Positive Results of a YG1699 Phase 2 Clinical Study Have Been Published by A Lea...
Does SGLT1 Inhibition Add to the Benefits of SGLT2 Inhibition in the Prevention ...
FDA's First Green Light for New Heart Failure Drug in Recent 4 Years
Youngene Therapeutics Meets with Cardiologists at AHA 2022 to Discuss the Potent...
Youngene Holds a Panel Discussion with Global Diabetes Experts at the EASD 2022 ...
CMO of Youngene Therapeutics will give a speech at the 2022EASD European Annual ...
Youngene Therapeutics ls Invited To Attend EASD This Year
First Patient Enrolled - YG1699 Type 1 Diabetes Phase llClinical Study in the Un...
Phase ll Clinical Trial Of YG1699 For Type l Diabetes Has BeenCarried Out In The...